Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[F 18]HX4 PET for Tumor Hypoxia
NCT01075399Phase 2Completed
- Sponsor
- Siemens AG
- Start
- Feb 2010
- Primary completion
- May 2011
- Modality
- Radiopharmaceutical
01
Overview
A Phase 2 trial of Flortanidazole F-18 in head and neck cancer (HNC), lung cancer, liver cancer, rectal cancer, Cervical Cancer (CC), sponsored by Siemens AG. Started Feb 2010; status: completed.
02
Drugs
Flortanidazole F-18
03
Conditions
head and neck cancer (HNC)lung cancerliver cancerrectal cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT01075399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01075399.